Zydus Lifesciences Ltd has achieved a significant milestone in its pharmaceutical endeavors with the recent confirmation from the US Food and Drug Administration (USFDA) for its generic version of the potent cancer treatment drug, Cyclophosphamide capsules.

In a formal statement released on Thursday, the company revealed that it has obtained the final green light from the US health regulatory body for Cyclophosphamide capsules, available in strengths of 25 mg and 50 mg. These capsules are slated to be manufactured at the formulation manufacturing facility located within Ahmedabad SEZ, India.

Cyclophosphamide, a vital chemotherapy medication renowned for its ability to impede the proliferation of cancer cells, is effective in treating various forms of cancer. Zydus Lifesciences highlighted its utility in addressing conditions such as lymphoma, myeloma, leukemia, breast cancer, and ovarian cancer, emphasizing the drug's critical role in combating these challenging diseases.

The company further divulged that Cyclophosphamide Capsules 25 mg and 50 mg amassed an annual sales figure of USD 6 million in the US market, according to IQVIA MAT (moving annual total) data from October 2023. This approval marks a significant advancement for Zydus Lifesciences in contributing to the accessibility and affordability of essential cancer therapies.

Zydus Lifesciences continues to underscore its commitment to providing high-quality and cost-effective pharmaceutical solutions, aiming to make a substantial impact on patients' lives battling various forms of cancer.